跳至主要内容
临床试验/NCT03240835
NCT03240835已完成不适用

The Function of Pre-Albumin, Retinol Conjugated Protein and Transferrin in Early Malnutrition Detecting and Nutritional Status Dynamic Monitoring for Local Advanced Nasopharyngeal Carcinoma Patients With Chemoradiotherapy

Zhao Chong1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年9月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
changes of PA/RBP/TRSF

研究概览

简要总结

The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)
  • •All genders,range from 18~60 years old
  • •Karnofsky performance status(KPS) ≥ 80
  • •Clinical stage III~IVb(UICC 8th)
  • •Without significant digestive system disease,nutritional and metabolic diseases or endocrine disease
  • •Without significant cardiac,respiratory,kidney or liver disease
  • •Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy)
  • •white blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, Hemoglobin(HGB) ≥ 10g/L, platelet(PLT) count ≥ 100×109/L
  • •alanine aminotransferase (ALT) or aspartate aminotransferase(AST) < 1.5×upper limit of normal(ULN), bilirubin < 1.5×ULN, alanine aminotransferase (CCR) ≥ 30ml/min
  • •Inform consent form

排除标准

  • •Distance metastases
  • •Second malignancy within 5 years
  • •Drug or alcohol addition
  • •Do not have full capacity for civil acts
  • •Active systemic infections
  • •Chronic consumptions
  • •Mental disorder
  • •Pregnancy or lactation
  • •Concurrent immunotherapy or hormone therapy for other diseases
  • •Severe complication, eg, uncontrolled hypertension

研究组 & 干预措施

CCRT±NACT

Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only

干预措施: IMRT (Radiation)

CCRT±NACT

Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only

干预措施: cisplatin and docetaxel (Drug)

结局指标

主要结局

changes of PA/RBP/TRSF

时间窗: baseline and during treatment

to evaluate the changes of PA/RBP/TRSF during the treatment

次要结局

  • Change of Body weight(baseline and during treatment)
  • Number of Participants With Abnormal Laboratory Values(baseline and during treatment)
  • Acute Toxicity(baseline and during treatment)

研究者

发起方
Zhao Chong
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Zhao Chong

Clinical Professor

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验